Published: 1 June 2017
Publications
Recent Approvals of Medicines Containing a New Active Ingredient
Prescriber Update 38(2): 28
June 2017
For period 16 January 2017 to 15 April 2017
Trade Name (active ingredient)* | Dose form and strength | Therapeutic area |
---|---|---|
Descovy (emtricitabine/ tenofovir)† | Tablet 200 mg/10 mg and 200 mg/25 mg | HIV-1 infection |
Eliriduc/Golyra/Praluent (alirocumab)§ | Solution for injection 75 mg/mL and 150 mg/mL | Hypercholesterolaemia |
Ilevro (nepafenac) | Eye drops, suspension 0.3% | Postoperative pain and inflammation associated with cataract surgery |
Perjeta (pertuzumab) | Concentrate for infusion 420 mg/14 mL | HER2-positive breast cancer |
Tecentriq (atezolizumab)# | Concentrate for infusion 1,200 mg/20 mL | Metastatic non-small cell lung cancer (NSCLC) or urothelial carcinoma |
* New active ingredient shown in bold type
† The new active ingredient in Descovy is tenofovir alafenamide fumarate (TAF), which replaces tenofovir disoproxil fumarate (TDF) in the related product Truvada
§ Not available
# Provisional consent
The data sheets for currently marketed prescription medicines are published on the Medsafe website (www.medsafe.govt.nz/profs/Datasheet/dsform.asp).